Elsevier

Peptides

Volume 12, Issue 5, September–October 1991, Pages 1007-1010
Peptides

Article
Effects of an ACTH/MSH(4–9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans

https://doi.org/10.1016/0196-9781(91)90051-PGet rights and content

Abstract

The synthetic ACTH/MSH(4–9) analog HOE 427 (“ebiratide”), which is behaviorally the most potent ACTH-derived peptide but which is devoid of endocrine activity, was administered intravenously in a pulsatile mode 4 times (120 μg each) at 2200, 2300, 2400 and 0100 to study its effect on the sleep EEG and on concomitant hormonal secretion of cortisol and growth hormone. In comparison to placebo, the peptide produced signs of general activation associated with specific deteriorating effects on the quality of sleep. Sleep onset latency and intermittent wakefulness were increased, slow wave sleep was reduced, but only during the first 3 hours of the sleep period. The nocturnal secretory patterns of cortisol and growth hormone were unaffected by HOE 427. These effects are different from those reported in similar studies in which corticotropin-releasing hormone (CRH) was applied in humans, and they suggest that peripherally administered neuropeptides have specific nonendocrine behavioral effects.

References (38)

Cited by (38)

  • Endocrinology of sleep

    2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second Edition
  • Stress & sleep: A relationship lasting a lifetime

    2020, Neuroscience and Biobehavioral Reviews
    Citation Excerpt :

    In young male volunteers, sleep electroencephalographic (EEG) activity changes occurred after pulsatile intravenous administration of ebiratide, an ACTH analog. Specifically, in these subjects NREM sleep decreased whereas sleep latency and wakefulness increased during the first third of the night (Steiger et al., 1991). In intact cats, ACTH infusions suppressed REM sleep (Koranyi et al., 1971) and, in rats, it significantly increased sleep latency and wake time while decreasing NREM sleep time (Tsutsui et al., 2015).

  • Effect of 5-HT2A receptor polymorphisms and occupational stress on self-reported sleep quality: A cross-sectional study in Xinjiang, China

    2016, Sleep Medicine
    Citation Excerpt :

    Various studies have also investigated the relationships between sleep quality and activation of the hypothalamic–pituitary–adrenal (HPA) axis, which is the major neuroendocrine system regulating stress responses via modulation of cortisol, adrenocorticotropic hormone (ACTH), and corticotropin-releasing hormone (CRH) levels [36]. CRH and ACTH infusion reduced slow-wave sleep during the sleep period and rapid eye movement (REM) during part of the sleep cycle, and also increased sleep latency [37,38], implying that stress perturbs normal sleep via HPA axis activation. Indeed, in the present study, subjects with high occupational stress – encompassing occupational role and personal strain – were at greater risk of poor sleep quality than those with low or moderate stress in both univariate and multivariate logistic regression analyses.

  • Neurochemical regulation of sleep

    2007, Journal of Psychiatric Research
    Citation Excerpt :

    The synthetic ACTH (4–9) analogue ebiratide shares several behavioural effects of ACTH but does not influence peripheral hormone secretion. Accordingly after repetitive i.v. ebiratide, GH and cortisol remain unchanged in young male controls, sleep onset increases, and during the first third of the night awake time is elevated and SWS decreases (Steiger et al., 1991). This observation corroborates the view that the blood–brain interface is no obstacle for CNS effects of i.v. administered neuropeptides, as ebiratide induces sleep-EEG changes in the absence of effects on peripheral hormone secretion.

  • Peptides And Sleep

    2006, Handbook of Biologically Active Peptides
View all citing articles on Scopus

Parts of this study were presented at the 10th Congress of the European Sleep Research Society, Strasbourg, May 20–25, 1990.

View full text